Enveric Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 28, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 28, 2025
ENVB$1.51+4.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| For the Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(9,574,987) | $(17,291,732) |
| Adjustments to reconcile net loss to cash used in operating activities | ||
| Change in fair value of warrant liability | (24,370) | (94,396) |
| Change in fair value of investment option liability | (21,620) | (208,752) |
| Change in fair value of derivative liability | — | (727,000) |
| Stock-based compensation | 1,562,392 | 2,150,160 |
| Inducement expense | — | 1,848,235 |
| Deferred offering costs expensed | 418,200 | — |
| Amortization of right of use asset | — | 64,048 |
| Amortization of intangibles | 168,750 | 168,754 |
| Depreciation expense | 168,739 | 175,228 |
| Gain on disposal of property and equipment | — | (4,206) |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 178,496 | (6,857) |
| Accounts payable and accrued liabilities | (834,630) | (103,848) |
| Due to related parties | 232,891 | — |
| Right-of-use operating lease asset and obligation | — | (64,045) |
| Net cash used in operating activities | (7,726,139) | (14,094,411) |
| Cash Flows From Investing Activities: | ||
| Purchases of property and equipment | — | (5,180) |
| Proceeds from disposal of property and equipment | — | 16,847 |
| Net cash provided by investing activities | — | 11,667 |
| Cash Flows From Financing Activities: | ||
| Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options | 1,804,819 | — |
| Proceeds from exercise of Inducement Warrants | 2,676,980 | — |
| Proceeds from common stock sold under the Equity Distribution Agreement, net of offering costs | 2,290,186 | — |
| Proceeds from common stock sold under the Purchase Agreement, net of offering costs | 1,083,706 | — |
| Payment for offering costs previously accrued | (181,857) | — |
| Payment for equity distribution offering costs | — | (291,084) |
| Redemption of Series A Preferred Stock | — | (1,052,057) |
| Net cash provided by (used in) financing activities | 7,673,834 | (1,343,141) |
| Effect of foreign exchange rate on changes on cash | 5,354 | (10,022) |
| Net decrease in cash | (46,951) | (15,435,907) |
| Cash at beginning of year | 2,287,977 | 17,723,884 |
| Cash at end of year | $2,241,026 | $2,287,977 |
| Supplemental disclosure of cash flow transactions: | ||
| Cash paid for interest | $— | $— |
| Income taxes paid | $5,000 | $9,507 |
| Non-cash financing and investing activities: | ||
| Stock subscription receivable | $— | $1,817,640 |
| Offering costs accrued not paid | $— | $182,724 |
| Warrants issued for offering costs | $— | $77,991 |
| Issuance of common shares for offering costs | $771,293 | $255,107 |
| Deferred offering costs charged to offering costs | $612,000 | $— |
| Induced conversion of warrants and preferred investment options | $— | $683,997 |
| Preferred dividends attributable to redeemable non-controlling interest | $— | $19,041 |
| Accretion of embedded derivative to redemption value | $— | $147,988 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.